CRL - Charles River Laboratories International, Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
Wilmington,
United States
Type: Equity
CRL price evolution
CRL
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $179.21 | $327.04 | $276.77 | |
| Short term investments | ||||
| Net receivables | $754.21 | $762.22 | $786.98 | $780.38 |
| Inventory | $336.2 | $349.11 | $361.28 | $380.26 |
| Total current assets | $1494.72 | $1499.27 | $1668.19 | $1608.66 |
| Long term investments | $231.86 | $243.54 | $243.81 | |
| Property, plant & equipment | $2025.11 | $2000.04 | $2003.1 | $2033.77 |
| Goodwill & intangible assets | $3879.82 | $3897.88 | $3959.1 | |
| Total noncurrent assets | $6449.01 | $6484.6 | $6586.34 | |
| Total investments | $231.86 | $243.54 | $243.81 | |
| Total assets | $8003.84 | $7948.28 | $8152.78 | $8195 |
| Current liabilities | ||||
| Accounts payable | $135.96 | $133.1 | $129.68 | $168.94 |
| Deferred revenue | $247.18 | $256.38 | $241.82 | |
| Short long term debt | ||||
| Total current liabilities | $1012.22 | $947.52 | $954.81 | $1055.08 |
| Long term debt | $2326.65 | $2837.97 | $3078.51 | $3066.38 |
| Total noncurrent liabilities | $3227.67 | $3494.05 | $3480.92 | |
| Total debt | $2837.97 | $3078.51 | $3066.38 | |
| Total liabilities | $4221.57 | $4175.19 | $4448.86 | $4536 |
| Shareholders' equity | ||||
| Retained earnings | $2122.84 | $2053.56 | $1959.78 | $1887.22 |
| Other shareholder equity | -$192.87 | -$269.71 | -$249.92 | -$196.43 |
| Total shareholder equity | $3722.73 | $3640.43 | $3596.88 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $276.77 | $233.91 | $241.21 | $228.42 |
| Short term investments | $1.02 | |||
| Net receivables | $780.38 | $752.39 | $642.88 | $617.74 |
| Inventory | $380.26 | $255.81 | $199.15 | $185.69 |
| Total current assets | $1608.66 | $1439.03 | $1274.1 | $1201.13 |
| Long term investments | $243.81 | $311.6 | $221.8 | |
| Property, plant & equipment | $2033.77 | $1857.42 | $1584.01 | $1302.58 |
| Goodwill & intangible assets | $3959.1 | $3805.18 | $3773.07 | $2596.77 |
| Total noncurrent assets | $6586.34 | $6163.74 | $5750.2 | $4289.7 |
| Total investments | $243.81 | $311.6 | ||
| Total assets | $8195 | $7602.77 | $7024.29 | $5490.83 |
| Current liabilities | ||||
| Accounts payable | $168.94 | $205.91 | $198.13 | $122.47 |
| Deferred revenue | $241.82 | $264.26 | $219.7 | $207.94 |
| Short long term debt | $2.79 | $50.21 | ||
| Total current liabilities | $1055.08 | $1091.59 | $1033.18 | $839.75 |
| Long term debt | $3066.38 | $2707.53 | $2916.54 | $2085.17 |
| Total noncurrent liabilities | $3480.92 | $3487.68 | $3399.11 | $2507.41 |
| Total debt | $3066.38 | $3097.28 | $2919.33 | $2135.38 |
| Total liabilities | $4536 | $4626.48 | $4432.3 | $3347.16 |
| Shareholders' equity | ||||
| Retained earnings | $1887.22 | $1432.9 | $980.75 | $625.41 |
| Other shareholder equity | -$196.43 | -$262.06 | -$164.74 | -$138.87 |
| Total shareholder equity | $3596.88 | $2976.29 | $2534.82 | $2114.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1026.12 | $1011.56 | $1013.48 | |
| Cost of revenue | $672.4 | $666.72 | $649.39 | |
| Gross Profit | $353.71 | $344.84 | $364.08 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $169.79 | $186.29 | $197.14 | |
| Total operating expenses | $202.06 | $218.87 | $231.16 | |
| Operating income | $151.65 | $125.98 | $132.92 | |
| Income from continuing operations | ||||
| EBIT | $152.24 | $132.49 | $240.38 | |
| Income tax expense | $25.39 | $24.53 | $19.75 | |
| Interest expense | $32.77 | $35 | $33.54 | |
| Net income | ||||
| Net income | $94.08 | $72.96 | $187.08 | |
| Income (for common shares) | $89.99 | $67.33 | $187.08 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4129.41 | $3976.06 | $3540.16 | $2923.93 |
| Cost of revenue | $2626.85 | $2513.41 | $2205.52 | $1850.39 |
| Gross Profit | $1502.56 | $1462.65 | $1334.64 | $1073.54 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $747.86 | $665.1 | $619.92 | $528.93 |
| Total operating expenses | $885.29 | $811.68 | $744.78 | $640.81 |
| Operating income | $617.26 | $650.98 | $589.86 | $432.73 |
| Income from continuing operations | ||||
| EBIT | $712.25 | $675.9 | $546.76 | $532.54 |
| Income tax expense | $100.91 | $130.38 | $81.87 | $81.81 |
| Interest expense | $136.71 | $59.29 | $73.91 | $86.43 |
| Net income | ||||
| Net income | $474.62 | $486.23 | $390.98 | $364.3 |
| Income (for common shares) | $474.62 | $486.23 | $390.98 | $364.3 |
| (in millions $) | 28 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $94.08 | $72.96 | $187.08 | |
| Operating activities | ||||
| Depreciation | $86.08 | $85.36 | $80.51 | |
| Business acquisitions & disposals | -$27.15 | -$13.87 | -$162.51 | |
| Stock-based compensation | $16.59 | $16.74 | $19.52 | |
| Total cash flows from operations | $193.53 | $129.89 | $220.94 | |
| Investing activities | ||||
| Capital expenditures | -$39.49 | -$79.14 | -$78.32 | |
| Investments | $4.86 | $7.5 | $2.71 | |
| Total cash flows from investing | -$168.98 | -$61.87 | -$85.79 | -$238.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$8.09 | $12.15 | $5.8 | |
| Net borrowings | -$254.54 | $8.4 | $122.55 | |
| Total cash flows from financing | -$475.05 | -$285.86 | $18.35 | $123.57 |
| Effect of exchange rate | -$4.03 | -$3.34 | -$8.39 | $12.72 |
| Change in cash and equivalents | -$72.84 | -$157.53 | $54.05 | $118.86 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $474.62 | $486.23 | $390.98 | $364.3 |
| Operating activities | ||||
| Depreciation | $314.12 | $303.87 | $265.54 | $234.92 |
| Business acquisitions & disposals | -$249 | -$278.39 | -$1215.96 | -$445.32 |
| Stock-based compensation | $72.05 | $73.62 | $71.47 | $56.34 |
| Total cash flows from operations | $683.9 | $619.64 | $760.8 | $546.58 |
| Investing activities | ||||
| Capital expenditures | -$318.53 | -$324.73 | -$228.77 | -$166.56 |
| Investments | $6.67 | $4.55 | $6.53 | $11.4 |
| Total cash flows from investing | -$563.15 | -$607.92 | -$1437.93 | -$601.54 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.44 | -$13.54 | $4.95 | $22.61 |
| Net borrowings | -$75.32 | $19.79 | $669.98 | $30.59 |
| Total cash flows from financing | -$85.52 | -$42.4 | $672.6 | $47.25 |
| Effect of exchange rate | $8.04 | $25.58 | $17.73 | $0.79 |
| Change in cash and equivalents | $43.27 | -$5.1 | $13.2 | -$6.93 |
News
Fundamentals
| Market cap | $9.50B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 51.13M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.26 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.48 |
| Quick ratio | 1.14 |